Kevin M.  Sun net worth and biography

Kevin Sun Biography and Net Worth

CFO of DermTech
Kevin Sun brings nearly two decades of corporate finance experience, including debt and equity financings, acquisitions, commercial product launches and infrastructure scaling and expansion projects mostly in the medical device and diagnostic industries. Previously, Mr. Sun served in various executive and management roles for DexCom, Inc., a NASDAQ-listed medical device company, including most recently as Vice President, Corporate Controller and Treasury, Interim Chief Financial Officer, and Vice President, Finance, and had key roles during a phase of significant growth and expansion. Prior to DexCom, Mr. Sun held various roles of increasing responsibility at Biosite Incorporated, a NASDAQ-listed leader in rapid point of care diagnostics. Mr. Sun holds a Bachelor of Science in Business with a dual major in Accounting and Finance, a minor in Psychology, a master’s degree in Strategic Management and an MBA from the Kelley School of Business at Indiana University.

What is Kevin M. Sun's net worth?

The estimated net worth of Kevin M. Sun is at least $0.00 as of December 11th, 2023. Mr. Sun owns 277,499 shares of DermTech stock worth more than $0 as of November 5th. This net worth approximation does not reflect any other investments that Mr. Sun may own. Additionally, Mr. Sun receives an annual salary of $600,350.00 as CFO at DermTech. Learn More about Kevin M. Sun's net worth.

How old is Kevin M. Sun?

Mr. Sun is currently 46 years old. There are 4 older executives and no younger executives at DermTech. The oldest executive at DermTech is Dr. Burkhard Jansen M.D., Chief Medical Affairs Officer, who is 58 years old. Learn More on Kevin M. Sun's age.

What is Kevin M. Sun's salary?

As the CFO of DermTech, Inc., Mr. Sun earns $600,350.00 per year. The highest earning executive at DermTech is Mr. Bret Christensen, President, CEO & Director, who commands a salary of $973,970.00 per year. Learn More on Kevin M. Sun's salary.

How do I contact Kevin M. Sun?

The corporate mailing address for Mr. Sun and other DermTech executives is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. DermTech can also be reached via phone at (858) 450-4222 and via email at [email protected]. Learn More on Kevin M. Sun's contact information.

Has Kevin M. Sun been buying or selling shares of DermTech?

Kevin M. Sun has not been actively trading shares of DermTech over the course of the past ninety days. Most recently, Kevin M. Sun sold 447 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $1.45, for a transaction totalling $648.15. Following the completion of the sale, the chief financial officer now directly owns 277,499 shares of the company's stock, valued at $402,373.55. Learn More on Kevin M. Sun's trading history.

Who are DermTech's active insiders?

DermTech's insider roster includes John Dobak (CEO), Claudia Ibarra (COO), Scott Pancoast (Director), Enrico Picozza (Director), Kevin Sun (CFO), and Todd Wood (Insider). Learn More on DermTech's active insiders.

Are insiders buying or selling shares of DermTech?

In the last year, insiders at the sold shares 5 times. They sold a total of 13,436 shares worth more than $20,494.84. The most recent insider tranaction occured on December, 11th when CFO Kevin M Sun sold 447 shares worth more than $648.15. Insiders at DermTech own 5.1% of the company. Learn More about insider trades at DermTech.

Information on this page was last updated on 12/11/2023.

Kevin M. Sun Insider Trading History at DermTech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2023Sell447$1.45$648.15277,499View SEC Filing Icon  
12/7/2023Sell4,979$1.53$7,617.87277,946View SEC Filing Icon  
9/11/2023Sell436$1.89$824.04282,925View SEC Filing Icon  
9/8/2023Sell9,180$1.93$17,717.40283,361View SEC Filing Icon  
6/12/2023Sell437$2.85$1,245.45290,041View SEC Filing Icon  
6/7/2023Sell4,988$2.53$12,619.64293,306View SEC Filing Icon  
3/13/2023Sell514$3.26$1,675.64298,294View SEC Filing Icon  
3/7/2023Sell8,687$4.06$35,269.22216,714View SEC Filing Icon  
9/6/2022Sell178$5.43$966.54222,901View SEC Filing Icon  
3/11/2022Sell435$14.55$6,329.25View SEC Filing Icon  
3/7/2022Sell726$13.03$9,459.78View SEC Filing Icon  
9/13/2021Sell622$36.19$22,510.18149,939View SEC Filing Icon  
9/8/2021Sell4,276$36.19$154,748.44View SEC Filing Icon  
6/11/2021Sell1,933$41.08$79,407.64154,478View SEC Filing Icon  
6/8/2021Sell2,870$43.43$124,644.10156,411View SEC Filing Icon  
3/8/2021Sell2,886$50.04$144,415.44View SEC Filing Icon  
See Full Table

Kevin M. Sun Buying and Selling Activity at DermTech

This chart shows Kevin M Sun's buying and selling at DermTech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DermTech Company Overview

DermTech logo
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.19
Low: $0.05
High: $0.42

2 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48